• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Strikeforce Technologies Inc
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

14.63 -0.74 (-4.81%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,331,011
Open 15.39
Bid (Size) 14.55 (5,000)
Ask (Size) 14.56 (2,300)
Prev. Close 15.37
Today's Range 14.56 - 15.41
52wk Range 12.07 - 29.23
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
October 05, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
October 02, 2026
From Summit Therapeutics
Via Business Wire

Performance

52-Week Range 49.9% below 52-week high
14.63
12.0752W Low 29.2352W High
1 Week 16.8% below 1-week high
14.561W Low 17.591W High

Summit Therapeutics Inc. - Common Stock (SMMT) traded between $12.07 and $29.23 over the past 52 weeks and last traded at $14.63, 49.9% below its 52-week high. Over the past week it ranged between $14.56 and $17.59.

Past 12 Months
-14.6%
-17.4%
+8.4%
-41.8%
-16.5%
-30.3%
1W -$2.50
1M -$3.09
3M +$1.13
6M -$10.49
YTD -$2.89
1Y -$6.36

SMMT was -30.3% over the past year, -41.8% over six months, -16.5% year to date, -14.6% in the last week.

12 Months vs Market
SMMT
-30.3%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months SMMT returned -30.3% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.72× 3-mo avg
Today 4,331,011 3-mo avg 6.0M
1W
5.0M
1M
7.2M
3M
6.0M
6M
5.7M
YTD
4.6M
1Y
4.2M

SMMT most recently traded 4,331,011 shares against a 3-month average daily volume of 6.0M.

More News

Read More
These stocks that are showing activity before the opening bell on Tuesday. ↗
September 29, 2026
Via Chartmill
News headline image
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
September 28, 2026
From Summit Therapeutics
Via Business Wire
Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst ↗
July 23, 2026
Via Chartmill
News headline image
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
September 22, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
September 15, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
September 13, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
September 02, 2026
From Summit Therapeutics
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
August 26, 2026
Via Benzinga
News headline image
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
August 25, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
August 25, 2026
From Summit Therapeutics
Via Business Wire
News headline image
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity ↗
August 24, 2026
Via The Motley Fool
News headline image
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
August 12, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
August 06, 2026
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
August 05, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Q2 Earnings Call Highlights ↗
July 23, 2026
Via MarketBeat
Topics Earnings
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
July 23, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
July 22, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
July 22, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
July 16, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
July 14, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
June 30, 2026
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Summit Therapeutics Announces Proposed Public Offering of Common Stock
June 09, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
June 04, 2026
From Summit Therapeutics
Via Business Wire

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 14.63
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.42B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap